Virtual Library

Start Your Search

J. Polanska



Author of

  • +

    P3.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 211)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Localized Disease - NSCLC
    • Presentations: 1
    • +

      P3.02-033 - Analysis of Factors That Have Impact on Adjuvant Chemotherapy Application in Operated Stage IIA-IV Non-Small Cell Lung Cancer Patients (ID 2388)

      09:30 - 09:30  |  Author(s): J. Polanska

      • Abstract
      • Slides

      Background:
      Surgery is the only potentially curative treatment in early stage non-small cell lung cancer (NSCLC). Even though relapse occurred in the majority of operated patients. Adjuvant chemotherapy is a standard management of an operable IIA –IV NSCLC, in order to reduce cancer recurrence and prolong overall survival. The aim of the study was to define the factors that reduce delivery of adjuvant chemotherapy.

      Methods:
      We performed a retrospective analysis of prospectively collected data of 498 IIA-IV NSCLC patients operated with radical intent between 2007 and 2013. Age, type and extension of surgery, presence of surgical complications, Charlson Comorbidity Index, forced vital capacity (FVC), forced expiratory volume in one second (FEV1), 6-minutes walk test (6MWT), marital status, distance between home to the hospital, duration of smoking habit, number of cigarettes smoked daily, number of packyears were considered in uni- and multivariate analysis for identification of factors that have potential influence the application adjuvant chemotherapy.

      Results:
      In univariate analysis age (p<0.001), 6MWT distance (p=0.007), FEV1 [dm3] (p<0.001), FEV1 (%) (p=0.006), FVC [dm3] (p<0.001), FVC (%) (p<0.001), complications after surgery (p=0.005), and type of surgery (p=0.036) were identified as factors that have impact on delivery of adjuvant chemotherapy. In the multivariate analysis, FVC [dm3] (p=0.043) and FEV1 [dm3] (p=0.013) were found as independent factors.

      Conclusion:
      Low pulmonary function tests limits delivery of complete adjuvant chemotherapy while age, comorbidity, type and extension of surgery has no impact in this regard.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.